Your browser doesn't support javascript.
loading
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
Li, Mengchu; Stevens, David L; Arriaga, Michelle; Townsend, E Andrew; Mendez, Rolando E; Blajkevch, Nadejda A; Selley, Dana E; Banks, Matthew L; Negus, S Stevens; Dewey, William L; Zhang, Yan.
Afiliación
  • Li M; Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Stevens DL; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Arriaga M; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Townsend EA; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Mendez RE; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Blajkevch NA; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Selley DE; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Banks ML; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Negus SS; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Dewey WL; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia23298, United States.
  • Zhang Y; Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.
ACS Chem Neurosci ; 13(24): 3608-3628, 2022 12 21.
Article en En | MEDLINE | ID: mdl-36449691
ABSTRACT
Discovery of analgesics void of abuse liability is critical to battle the opioid crisis in the United States. Among many strategies to achieve this goal, targeting more than one opioid receptor seems promising to minimize this unwanted side effect while achieving a reasonable therapeutic profile. In the process of understanding the structure-activity relationship of nalfurafine, we identified a potential analgesic agent, NMF, as a dual kappa opioid receptor/delta opioid receptor agonist with minimum abuse liability. Further characterizations, including primary in vitro ADMET studies (hERG toxicity, plasma protein binding, permeability, and hepatic metabolism), and in vivo pharmacodynamic and toxicity profiling (time course, abuse liability, tolerance, withdrawal, respiratory depression, body weight, and locomotor activity) further confirmed NMF as a promising drug candidate for future development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Analgésicos Opioides / Morfinanos Límite: Humans Idioma: En Revista: ACS Chem Neurosci Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Analgésicos Opioides / Morfinanos Límite: Humans Idioma: En Revista: ACS Chem Neurosci Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...